Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment

Cancer Treatment Reviews

Volumn 35, Issue 4, 2009, Pages 354-363

  Capdevila, Jaume ^a   Elez, Elena ^a   Macarulla, Teresa ^a   Ramos, Francisco Javier ^a   Ruiz Echarri, Manuel ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cetuximab; Colorectal cancer; EGFR; Matuzumab; Monoclonal antibodies; Non small cell lung cancer; Panitumumab; Squamous cell head and neck cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MATUZUMAB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ACNE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CANCER; INFECTION; KIDNEY CANCER; KIDNEY CARCINOMA; LARYNX CANCER; LOADING DRUG DOSE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; NONHUMAN; OROPHARYNX CANCER; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERITONEUM CANCER; PROSTATE CANCER; RECOMMENDED DRUG DOSE; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TUMOR REGRESSION; UTERINE CERVIX CARCINOMA;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67349143074     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.02.001     Document Type: Review

References (84)

1. Hanahan D., and Weinberg R. The hallmarks of cancer. Cell 100 1 (2000) 57-70
2. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 1 (2000) 12-21
3. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21 14 (2003) 2787-2799
4. Ullrich A., Coussens L., Hayflick J.S., et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309 5967 (1984) 418-425
5. Ogiso H., Ishitani R., Nureki O., et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110 6 (2002) 775-787
6. He C., Hobert M., Friend L., and Carlin C. The epidermal growth factor receptor juxtamembrane domain has multiple basolateral plasma membrane localization determinants, including a dominant signal with a polyproline core. J Biol Chem 277 41 (2002) 38284-38293
7. Castagnino P., Biesova Z., Wong W.T., Fazioli F., Gill G.N., and Di Fiore P.P. Direct binding of eps8 to the juxtamembrane domain of EGFR is phosphotyrosine- and SH2-independent 10 4 (1995) 723-729
8. Wells A. EGF receptor. Int J Biochem Cell Biol 31 (1999) 637-643
9. Lewis T.S., Shapiro P.S., and Ahn N.G. Signal transduction through MAP kinase cascades. Adv Cancer Res 74 (1998) 49-139
10. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
11. Alroy I., and Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410 (1997) 83-86
12. Burgering B.M., and Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376 (1995) 599-602
13. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor - positive tumors. A new paradigm for cancer therapy. American Cancer Society 2002;94(5):1593-1611.
14. Brabender J., Danenberg K.D., Metzger R., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7 7 (2001) 1850-1855
15. Wikstrand C.J., Hale L.P., Batra S.K., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55 14 (1995) 3140-3148
16. Chu C.T., Everiss K.D., Wikstrand C.J., Batra S.K., Kung H.J., and Bigner D.D. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324 3 (1997) 855-861
17. Nakamura K., Koike M., Shitara K., et al. Chimeric anti-ganglioside GM2 antibody with antitumor activity. Cancer Res 54 6 (1994) 1511-1516
18. Riechmann L., Clark M., Waldmann H., and Winter G. Reshaping human antibodies for therapy. Nature 332 6162 (1988) 323-327
19. Jakobovits A., Vergara G.J., Kennedy J.L., et al. Analysis of homozygous mutant chimeric mice. deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production. PNAS 90 6 (1993) 2551-2555
20. Green L.L., Hardy M.C., Maynard-Currie C.E., et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 7 1 (1994) 13-21
21. Herbst R.S., Kim E.S., and Harari P.M. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 1 (2001) 719-732
22. Fan Z., Shang B.Y., Lu Y., Chou J.L., and Mendelsohn J. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 3 11 (1997) 1943-1948
23. Bruns C.J., Solorzano C.C., Harbison M.T., et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60 11 (2000) 2926-2935
24. Perrotte P., Matsumoto T., Inoue K., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5 2 (1999) 257-264
25. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., and Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 11 (1995) 1311-1318
26. Saltz L., Rubin M., Hochster H., et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer that express the epidermal growth factor receptor. Proc Am Soc Clin Oncol 20 3a (2001)
27. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 7 (2004) 1201-1208
28. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
29. Van Cutsem E., Nowacki M., Lang I., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Proc Am Soc Clin Oncol 25 18S (2007) 4000
30. Saltz L., Kies M., Abbruzzese J.L., Azarnia N., and Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22 (2003) 817
31. Tejpar S., Peeters M., Humblet Y., et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. Proc Am Soc Clin Oncol 25 18S (2007) 4037
32. Tabernero J., Cervantes A., Martinelli E., et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 24 18S (2006) 3085
33. Lievre A., Bachet J.-B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 8 (2006) 3992-3995
34. Van Cutsem E., Lang I., D'haens G., et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. Proc Am Soc Clin Oncol 26 (2008) 2
35. Van Cutsem E., Lang I., D'Haens G., et al. Kras status and efficacy in the CRYSTAL study: 1st-line treatment of patients with metastatic colorectal cancer (mCRC) receiving FOLFIRI with or without cetuximab. Ann Oncol 19 8S (2008) VIII1-VIII4
36. Bokemeyer C., Bondarenko I., Makhson A., et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. Proc Am Soc Clin Oncol 25 18S (2007) 4035
37. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. Proc Am Soc Clin Oncol 26 20S (2008) 4000
38. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26 14 (2008) 2311-2319
39. Ciardiello F., Bianco R., Damiano V., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6 9 (2000) 3739-3747
40. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5 3 (2007) 203-220
41. Saltz L.B., Lenz H.-J., Kindler H.L., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25 29 (2007) 4557-4561
42. Hecht J.R., Mitchell E., Chidiac T., et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. J Clin Oncol 27 5 (2009) 672-680
43. Tol J., Koopman M., Rodenburg C.J., et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19 4 (2008) 734-738
44. Huang S.M., and Harari P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drug 17 (1999) 259-269
45. Huang S.-M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 6 (2000) 2166-2174
46. Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19 13 (2001) 3234-3243
47. Baselga J., Trigo J.M., Bourhis J., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23 24 (2005) 5568-5577
48. Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 24 (2005) 5578-5587
49. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
50. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 11 (2008) 1116-1127
51. Rosell R., Robinet G., Szczesna A., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19 2 (2008) 362-369
52. Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008;26:3.
53. Thienelt C.D., Bunn Jr. P.A., Hanna N., et al. Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 23 34 (2005) 8786-8793
54. Robert F., Blumenschein G., Herbst R.S., et al. Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 23 36 (2005) 9089-9096
55. Butts C.A., Bodkin D., Middleman E.L., et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer. J Clin Oncol 25 36 (2007) 5777-5784
56. Lynch TJ, Patel T, Dreisbach L, et al. A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2(4S):B3-03.
57. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Proc Am Soc Clin Oncol 2008;26(20S):1009.
58. Hobday TJ, Stella PJ, Fitch TR, et al. N0436: a phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy. Proc Am Soc Clin Oncol 2008;26(20S):1081.
59. Xiong H.Q., Rosenberg A., LoBuglio A., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22 13 (2004) 2610-2616
60. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Proc Am Soc Clin Oncol 2007;25(18S):4509.
61. Motzer R.J., Amato R., Todd M., et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drug 21 1 (2003) 99-101
62. Bellone S., Frera G., Landolfi G., et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 106 3 (2007) 513-520
63. Yang X.D., Jia X.C., Corvalan J.R., Wang P., and Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 1 (2001) 17-23
64. Yang X.-D., Jia X.-C., Corvalan J.R.F., Wang P., Davis C.G., and Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer Res 59 6 (1999) 1236-1243
65. Weiner L.M., Belldegrun A.S., Crawford J., et al. Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies. Clin Cancer Res 14 2 (2008) 502-508
66. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 2005;23(16S):3520.
67. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 13 (2007) 1658-1664
68. Hecht JR, Chidiac T, Mitchell E, et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC). In: World Congress on Gastrointestinal Cancer 2007, Abstract O-0033.
69. Crawford J, Sandler AB, Hammond LA, et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;22(14S):7083.
70. Vanhoefer U., Tewes M., Rojo F., et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22 1 (2004) 175-184
71. Seiden M.V., Burris H.A., Matulonis U., et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 104 3 (2007) 727-731
72. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67 6 (2007) 2643-2648
73. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 35 (2008) 5705-5712
74. Jhawer M., Goel S., Wilson A.J., et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68 6 (2008) 1953-1961
75. Perrone F., Lampis A., Orsenigo M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20 1 (2009) 84-90
76. Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002;21:536.
77. Folprecht G, Lutz M, Schoeffski P, et al. Cetuximab/irinotecan/high-dose-5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). In: ASCO Gastrointestinal Cancers Symposium, 2004. p. 283.
78. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 2004;22(14S):3513.
79. Arnold D., Hohler T., Dittrich C., et al. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 19 8 (2008) 1442-1449
80. Tabernero J., Van Cutsem E., Diaz-Rubio E., et al. Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer. J Clin Oncol 25 33 (2007) 5225-5232
81. Dakhil S, Cosgriff T, Headley D, Badarinath S. Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer (an international oncology network study, I-03-002). Proc Am Soc Clin Oncol 2006;24(18S):3557.
82. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc Am Soc Clin Oncol 2006;24(18S):3509.
83. Colucci G, Giuliani F, Mattioli R, et al. FOLFOX-4 + cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the gruppo oncologico dell'italia meridionale (prot. GOIM 2402). Proc Am Soc Clin Oncol 2006;24(18S):3559.
84. Borner M., Koeberle D., Von Moos R., et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 19 7 (2008) 1288-1292